Abinitio Bio
Foundation model
YC-backed startup building foundation models for biomanufacturing (first model 'Echo'), predicting process, cell-line and developability outcomes validated against wet-lab data.
Abinitio Bio builds frontier foundation models for biomanufacturing — an 'intelligence layer for drug manufacturing.' Its first model, Echo, predicts biological manufacturing outcomes (upstream bioprocess conditions, cell-line behaviour and molecular developability) more accurately than standard hybrid models, validated against wet-lab data, and any pharma or CDMO can adapt it to their workflow. The platform spans manufacturability assessment, process-development modelling, process characterisation and delivered validated assets for scale-up. It targets a biologics cell-line campaign that costs $5-10M and takes 12-18 months, aiming to compress decisions that take 6-18 months today into hours and de-risk programs that would otherwise be killed at CMC/manufacturing.
Research mapping
Healthspan / Manufacture (AI) / Foundation model
Evidence boundary
Original analysis and independent corroboration remain under development. Commercial scale and durable technical advantage remain under review.
What makes it defensible
Wet-lab-validated foundation models for bioprocess outcomes that transfer across molecules and sites — closing the manufacturing data gap that generic models cannot.
Position in the stack: AI prediction layer bridging drug discovery and commercial biologics manufacturing — de-risks CMC and scale-up, where otherwise-good molecules are routinely abandoned.
Who buys it
Founding team
Daniel Mukasa — Founder & CEO — PhD Applied Physics & Materials Science, Caltech; postdoctoral fellow at MIT (AI + drug discovery); ex-AI/ML at Merck; Caltech/Merck/MIT/Broad
SourceFinancing detail
- Last round
- Seed
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.